Why the study?
Does apixaban reduce stroke and other thromboembolic events compared to warfarin in patients with atrial fibrillation?
Does apixaban reduce stroke and other thromboembolic events compared to warfarin in patients with atrial fibrillation?
Answers are grounded in this paper and cite their sources.
This editorial discusses the ARISTOTLE trial, highlighting the shift from warfarin to alternative oral anticoagulants like apixaban for stroke prevention in atrial fibrillation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Jessica L. Mega (2011) conducted an editorial in Atrial Fibrillation. Apixaban vs. Warfarin was evaluated on Stroke and other thromboembolic events.
Synapse has enriched 10 related papers. Consider them for comparative context: